New Zealand markets closed

LLY Jan 2025 330.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.28000.0000 (0.00%)
At close: 09:32AM EDT
Full screen
Previous close0.2800
Open0.2800
Bid0.4000
Ask0.9000
Strike330.00
Expiry date2025-01-17
Day's range0.2800 - 0.2800
Contract rangeN/A
Volume1
Open interest145
  • Investor's Business Daily

    Dow Jones Futures: Narrowing Market Rally Keeps Rising; 7 Stocks Near Buy Points

    The market rally had a mixed week as breadth narrowed. Microsoft and Merck led stocks near buy points. Here's what to do.

  • Yahoo Finance Video

    Ether ETF approved, Live Nation antitrust suit: Morning Brief

    After an eventful week compounded by Nvidia's (NVDA) fiscal first-quarter earnings, the major market averages (^DJI, ^IXIC, ^GSPC) are hoping to end the week on a high note and claw back some gains ahead of the Memorial Day Weekend. Morning Brief Hosts Seana Smith and Brad Smith walk investors through the top stories moving stocks in Friday's trading day, kicking off the session with Truist Co-Chief Investment Officer and Chief Market Strategist Keith Lerner who compares the market sway of Nvidia's latest earnings to that of inflation data or the Federal Reserve's monetary policy. The Securities and Exchange Commission (SEC) approved ether ETF offerings on Thursday, leading Bloomberg Intelligence ETF Research Analyst James Seyffart to believe ethereum-exposed (ETH-USD) products will have similar success to the spot bitcoin ETFs (BTC-USD) rolled out at the start of 2024, just not on the same scale. Other top trending stories include the latest in the Department of Justice's (DOJ) antitrust suit against concert promoter and ticket seller Live Nation (LYV) and Charter Communications' (CHTR) content distribution deal with Paramount Global (PARA). This post was written by Luke Carberry Mogan.

  • Associated Press Finance

    Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, Mounjaro

    Eli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its popular weight-loss and diabetes treatments, Zepbound and Mounjaro. The company broke ground for its Lebanon, Indiana, manufacturing plant last year and expects to start making products there near the end of 2026. Lilly said it would add $5.3 billion to the $3.7 billion it had already slated for the site.